{
  "content": "Diagnosis:\t\tMetastatic lung adenocarcinoma, left lower lobe\n\nStaging:\t\tT3N2M1b KRAS G12V mutant, EGFR wild type\n\tCT 15 March 2024: 4.8cm left lower lobe mass with mediastinal nodes, multiple liver metastases and bone involvement\n\nTreatment:\t\tCycle 3 Carboplatin/Pemetrexed completed 10 April 2024\n\nMDT Discussion:\tLung MDT 18 April 2024\n\nRadiology review confirms stable disease with primary mass measuring 4.6cm (previously 4.8cm), stable liver metastases, and no new sites of disease. Blood results show stable biochemistry and acceptable haematological parameters for continuation of treatment.\n\nMDT Recommendation:\t1. Continue with planned cycle 4 Carboplatin/Pemetrexed\n\t\t\t2. Arrange interval CT chest/abdomen/pelvis after cycle 4\n\t\t\t3. Review in medical oncology clinic with scan results\n\nPlan:\t\tProceed with cycle 4 chemotherapy on 24 April 2024\n\t\tCT scan booked for 15 May 2024\n\t\tClinic review arranged for 22 May 2024",
  "output": {
    "primary_cancer": {
      "site": "lung, left lower lobe",
      "year": 2024,
      "month": 3,
      "metastases": "multiple liver metastases and bone involvement",
      "tnm_stage": "T3N2M1b",
      "histopathology_status": "adenocarcinoma",
      "biomarker_status": "KRAS G12V mutation positive, EGFR negative",
      "cancer_timeline": [
        {
          "type": "anatomical_finding",
          "value": "CT shows 4.8cm left lower lobe mass with mediastinal nodes, multiple liver metastases and bone involvement",
          "year": 2024,
          "month": 3
        },
        {
          "type": "treatment_systemic_start",
          "value": "Started on Carboplatin/Pemetrexed chemotherapy",
          "year": 2024,
          "month": 3
        },
        {
          "type": "treatment_systemic_change",
          "value": "Completed cycle 3 Carboplatin/Pemetrexed",
          "year": 2024,
          "month": 4
        },
        {
          "type": "anatomical_finding",
          "value": "CT shows stable disease with primary mass measuring 4.6cm, stable liver metastases, no new sites of disease",
          "year": 2024,
          "month": 4
        }
      ]
    },
    "patient_facts": [
      {
        "type": "investigation_finding",
        "value": "Stable biochemistry and acceptable haematological parameters"
      }
    ],
    "status_updates": [
      {
        "type": "clinical_summary",
        "value": "Metastatic KRAS mutant lung adenocarcinoma showing stable disease after 3 cycles of first-line chemotherapy"
      },
      {
        "type": "latest_treatment_response",
        "value": "Stable disease with minimal reduction in primary mass size from 4.8cm to 4.6cm"
      },
      {
        "type": "update_to_treatment",
        "value": "Continue with planned cycle 4 Carboplatin/Pemetrexed on 24 April 2024"
      },
      {
        "type": "planned_investigation",
        "value": "CT chest/abdomen/pelvis scheduled for 15 May 2024"
      },
      {
        "type": "follow_up_referral",
        "value": "Medical oncology clinic review with scan results on 22 May 2024"
      }
    ]
  }
}